
- December 2012 Heart Health
- Volume 78
- Issue 12
Your Compounding Questions Answered
Q: Can you provide a liquid formulation for vancomycin HCl?
A: Vancomycin HCl, a glycopeptide antibiotic, is used to treat gram-positive bacterial infections, most notably pseudomembranous colitis caused by the anaerobic bacillus Clostridium difficile. This form of colitis is often seen as an iatrogenic infection following large-dose antibiotic therapy that kills much of normal gut flora, and can in extreme cases lead to toxic megacolon and death.
Vancomycin HCl is administered as a parenteral solution or oral capsule (125 and 250 mg/capsule). Therapeutic compliance can be enhanced by administration of oral liquid preparations in selected cases.
Oral liquid preparations of vancomycin HCl for oral solution formerly were available as 500 mg/6 mL and 250 mg/5 mL (Vancoled, Lederle; Vancocin HCl, Viropharma), but currently are listed in the FDA Orange Book as “discontinued.”
Several formulations for extemporaneous preparation of vancomycin HCl oral solution have been published. One recent example uses a unique vehicle to compound vancomycin 50 mg/mL (Whaley PA, Voudrie MA II. Stability of vancomycin in SyrSpend SF. Int J Pharm Compounding. 2012;16(2):167-169).
Suggested Formulation
- Vancomycin HCl 5 g
- SyrSpend SF q.s. ad 100 mL Suggested Method Calculate the required quantity of each ingredient for the total amount of formulation to be prepared. Accurately weigh and/or measure each ingredient; reduce powders to fine consistency with ceramic or Wedgwood mortar and pestle. Add a small amount of SyrSpend SF to the vancomycin HCl to wet the powder; mix well. Transfer mixture in (3) to a graduated cylinder of sufficient capacity. Add sufficient SyrSpend SF to reach desired calculated volume by “washing” the mortar and pestle in (4) with 2 to 3 aliquots of SyrSpend SF into the graduated cylinder to ensure all active ingredient is transferred. Package and label. Consider “Shake Well” and “Refrigerate” labeling. The authors assigned BUD 90 days when refrigerated and protected from light. Mr. Erickson is quality assurance and regulatory affairs manager at Fagron, Inc. (Fagron US).
Articles in this issue
almost 13 years ago
Pharmacogenomics and the Most Commonly Prescribed Drugs of 2011almost 13 years ago
Improving Heart Health with Better Sleepalmost 13 years ago
Obstructive Sleep Apnea: An Important Wake-Up Callalmost 13 years ago
Can You Read These Rxs?almost 13 years ago
Case Studiesalmost 13 years ago
Systems Problems Among Roots of Tech-Related Medication Errorsalmost 13 years ago
The Power of Words: A New Approach to Counselingalmost 13 years ago
Pharmacist Terminated in Violation of Public Policy?almost 13 years ago
New FDA Board to Handle Exclusivity Decisionsalmost 13 years ago
Medical Journal Piece Suggests Solutions to Generic Labeling QuandaryNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.